Citadel Advisors
BRNS

Citadel Advisors’s Barinthus Biotherapeutics BRNS Stock Holding History

Citadel Advisors’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.7K Sell
76,754
-42,242
-35% -$27.5K ﹤0.01% 13109
2026
Q1 		$68.1K Buy
118,996
+197
+0.2% +$130 ﹤0.01% 12267
2025
Q4 		$83.2K Buy
+118,799
New +$119K ﹤0.01% 11773
2025
Q3 		– Sell
-16,227
Closed -$14.8K – 12814
2025
Q2 		$14.8K Sell
16,227
-9,945
-38% -$8.69K ﹤0.01% 12161
2025
Q1 		$25.9K Buy
+26,172
New +$26.9K ﹤0.01% 12941
2024
Q4 		– Sell
-27,717
Closed -$34.1K – 14535
2024
Q3 		$34.1K Buy
27,717
+11,680
+73% +$15.7K ﹤0.01% 12315
2024
Q2 		$22.5K Buy
+16,037
New +$36.2K ﹤0.01% 12537
2023
Q3 		– Sell
-14,877
Closed -$30.6K – 14313
2023
Q2 		$30.6K Buy
+14,877
New +$35.2K ﹤0.01% 12333
2023
Q1 		– Sell
-17,383
Closed -$41.5K – 14735
2022
Q4 		$41.5K Buy
+17,383
New +$44.3K ﹤0.01% 12367

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors's BRNS Position: Q2 2026 in Review

Citadel Advisors reduced its Barinthus Biotherapeutics (BRNS) stake by 35% in Q2 2026, selling an estimated $27.5K and leaving 76,754 shares worth $50.7K. The position accounts for ﹤0.01% of the portfolio, ranked #13109.

Citadel Advisors first reported a position in BRNS in Q4 2022 and has held it in 9 quarters since. The position peaked at $83.2K in Q4 2025. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

  • Citadel Advisors held 76,754 shares of Barinthus Biotherapeutics worth $50.7K as of Q2 2026.
  • Citadel Advisors sold 42,242 Barinthus Biotherapeutics shares in Q2 2026, an estimated $27.5K.
  • Barinthus Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13109 holding.
  • Citadel Advisors first reported a position in Barinthus Biotherapeutics in Q4 2022 and has held it in 9 quarters since.
  • Citadel Advisors's Barinthus Biotherapeutics position peaked at $83.2K in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.